Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 70, Issue 2, 1998, Pages 267-271

  Rose, Peter G ^a   Blessing, John A ^b   Soper, John T ^c   Barter, James F ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CREATININE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; LEIOMYOSARCOMA; LIVER FUNCTION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UTERUS SARCOMA; VOMITING;

EID: 0031713674     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5080     Document Type: Article

References (38)

1. Montague A C, Swartz D P, Woodruff J D. Sarcoma arising in a leiomyoma of the uterus. Am J Obstet Gynecol. 92:1965;421-427.
2. Berchuck A, Rubin S C, Hoskins W J, Saigo P E, Pierce V K, Lewis J L Jr. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 71:1988;845-850.
3. Leibsohn S, d'Ablaing G, Mishell D R, Schlaerth J B. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 162:1990;968-976.
4. Corscaden J A, Singh B P. Leiomyosarcoma of the uterus. Am J Obstet Gynecol. 75:1958;149-155.
5. Hannigan E V, Gomez, LG. Uterine leiomyosarcoma. Am J Obstet Gynecol. 134:1979;557-564.
6. Boutselis J G, Ullery J C. Sarcoma of the uterus. Obstet Gynecol. 20:1962;23-35.
7. Major F J, Blessing J A, Silverberg S G, Morrow C P, Creasman W T, Currie J L, Yordan E, Brady M F. Prognostic factors in early-stage uterine sarcoma. Cancer. 71:1993;1702-1709.
8. Omura G A, Blessing J A, Major F, Lifshitz S, Mangan C, Beecham J, Park R, Silverberg S. A randomization clinical trial of adjuvant adriamycin in uterine sarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 3:1985;1240-1245.
9. Omura G A, Major F J, Blessing J A, Sedlacek T V, Thigpen J T, Creasman W T, Zaino R J. A randomized study of adriamycin with and without dimethyl triazinoimidazole carboxamide in advanced uterine sarcomas. Cancer. 52:1983;626-632.
10. Sutton G, Blessing J, Barrett R J, Ramon Mc Gehee. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Obstet Gynecol. 166:1992;556-559.
11. Sutton G, Blessing J A, Malfetano J H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 62:1996;226-229.
12. Thigpen J T. Chemotherapy of cancers of the female genital tract. The Chemotherapy Source Book. 1992;Williams & Wilkins, Baltimore. p. 1045.
13. Slayton R E, Blessing J A, Angel C, Berman M. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer. 71:1987;1303-1304.
14. Ross W, Rowe T, Glisson B, Yalowich J, Lui L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 44:1984;5857-5860.
15. Dombernowsky P, Nissen N I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Path Microbiol Scand. 81:1973;715-724.
16. Slevin M L, Clark P I, Joel S P, Malik S, Osborne R J, Gregory W M, Lowe D G, Reznek R H, Wrigley P FM. A randomized trial to evaluate the effect the effect of schedule on the activity of etoposide in small-cell lung. J Clin Oncol. 7:1989;1333-1340.
17. Cavelli F, Sonntag R W, Jungi F, Senn H J, Brunner K W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 62:1978;473-475.
18. Hainsworth J D, Johnson D H, Frazier S R, Greco F A. Chronic daily administration of oral etoposide-A phase I trial. J Clin Oncol. 7:1989;396-401.
19. Martin M, Lluch A, Casado A, Santabarbara P, Adrover E, Valverde J J, Lopez-Martin J A, Rodriguez-Lescure A, Azagra P, Garcia-Conde J, Diaz-Rubio E. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol. 12:1994;986-991.
20. Waits T M, Johnson D H, Hainsworth J D, Hande K R, Thomas M, Greco F A. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol. 10:1992;292-296.
21. Miller A A, Tolley E A, Niell H B, Griffin J P, Mauer A M. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 11:1993;1179-1188.
22. Dombernowsky P, Buesa J, Pinedo H M, Santoro A, Mouridsen H, Somers R, Bramwell V, Onsrud M, Rouesse J, Thomas D, Sylvester R. VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol. 23:1987;579-580.
23. Hainsworth J D, Johnson D H, Frazier S R, Greco F A. Chronic daily administration of oral etoposide-a phase I trial. J Clin Oncol. 7:1989;839-401.
24. Licht J D, Mazanet R, Loehrer P J, Gonin R, Antman K H. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 34:1994;79-80.
25. Kampe C E, Lowenbraun S, Foster J, Rosen G. Oral etoposide in treatment of advanced refractory sarcomas. J Natl Cancer Inst. 84:1992;1836-1837.
26. Chantarawiroj P, Tresukosol D, Kudelka A, Edwards C L, Edwards C L, Silva E G, Wharton J T, Kavanagh J J. Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma. Gynecol Oncol. 58:1995;248-250.
27. Termrunglert W, Kudelka A P, Piamsomboon S, Edwards C L, Tornos C, Kavanagh J J. Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastasis: case report. Eur J Gynecol Oncol. 18:1997;97-100.
28. Seki H, Takagi A, Takada S, Takeda S, Kinoshita K, Masunaga A, Sugawara I, Itoyama S. A case of recurrent intramural uterine stromal tumor with epithelial differentiation effectively treated with oral low-dose administration of etoposide. Asia-Oceania J Obstet Gynecol. 20:1994;59-65.
29. Lin Y C, Kudelka A P, Tresukosol D, Malpica A, Carrasco C H, Lawrence D D, Collier R E, Munoz A, Delclos L, Kavanagh J J, Edwards C L. Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. Gynecol Oncol. 58:1995;262-265.
30. Ilstrup D M. Randomized clinical trials: potential cost savings due to the identification ineffective medical therapies. Mayo Clin Proc. 70:1995;707-710.
31. Johnson D H, Greco F A, Strupp J, Hande K R, Hainsworth J D. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 8:1990;1613-1617.
32. Martin M, Lluch A, Casado A, Santabarbara P, Adrover E, Valverde J J, Lopez-Martin J A, Rodriguez-Lescure A, Azagra P, Garcia-Conde J, Diaz-Rubio E. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol. 12:1994;986-991.
33. Hainsworth J D, Johnson D H, Greco F A. Chronic daily administration of oral etoposide in refractory lymphoma: a phase II trial. Eur J Cancer. 26:1990;818-821.
34. Rose P G, Blessing J S, Lewandowski G S, Creasman W T, Webster K D. A phase II trial of prolonged oral etoposide as second line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 63:1996;101-104.
35. Ratain M J, Kaminer L S, Bitran J D, Larson R A, Le Beau M M, Skosey C, Purl S, Hoffman P C, Wade J, Vardiman J W, Daley K, Rowley J D, Golomb H M. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 70:1987;1412-1417.
36. Pui C H, Ribeiro R C, Hancock M L, Rivera G K, Evans W E, Raimondi S C, Head D R, Behm F G, Mahmoud M H, Sandlund J T, Crist W M. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 325:1991;1682-1687.
37. Whitlock J A, Greer J P, Lukens J N. Epipodophyllotoxin-related leukemia: identification of a new subset of secondary leukemia. Cancer. 68:1991;600-604.
38. Smith M A, McCaffrey R P, Karp J E. The secondary leukemias: challenges and research directions. J Natl Cancer Inst. 88:1996;407-418.